News
OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture
New expedited service line designed for biotechs with timeline constraints, launched in response to client demand Can accelerate timeline to GMP manufacturing by up to nine months, driven by key innovations and efficiencies across upstream and downstream processes Oxford, UK……
View details >OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards
Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the CDMO Leadership Awards……
View details >Preliminary results for the year ended 31 December 2025
A year of strategic execution, strong revenue growth and positive Operating EBITDA Strong 2025 financial performance; revenues at upper end of guidance, with full year Operating EBITDA profitability achieved: Revenue growth of 33% to £170.9 million (CC) (FY 2024: £128.8……
View details >OXB enters into licensing agreement with Viral Vector Manufacturing Facility (VVMF), providing access to its AAV and LV viral vector platforms
Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into……
View details >OXB announces date for Capital Markets Day and participation in upcoming investor conferences
Oxford, UK – 3 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces the date of its Capital Markets Day and participation at upcoming investor conferences. Capital Markets Day OXB will hold……
View details >Full year Trading Update and Notice of Results
Revenues at the upper end of guidance and pivot to EBITDA profitability – expectations for 2026 unchanged and guidance reiterated Revenues expected to increase c.30% as OXB continues to execute its strategy, FY 2025 revenues expected to be £166-169……
View details >OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb
OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmes Multi-year agreement with five-year initial term and option to extend Oxford, UK – 4 February 2026: OXB (LSE: OXB), a global quality and innovation-led cell……
View details >OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category
Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards……
View details >OXB to participate in upcoming investor conferences and events
Oxford, UK – 27 October 2025:OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that members of its senior management team, including Dr. Frank Mathias, Chief Executive Officer, and Dr. Lucy Crabtree, Chief Financial……
View details >
